We need a Global Vaccines Taskforce, not just a British or European one
The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...
Medicines Patent Pool signs first Covid-19 licence agreement with Merck Sharp & Dohme. Others...
The Medicines Patent Pool, a UN-backed organisation whose mission is to expand access to essential medicines around the world, today announced its first agreement...
The Power of TRIPS Flexibilities in Medicines Procurement
The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV). Treatment will be a combination of...
Medicines Law & Policy statement at WHO PABS negotiations (IGWG 5)
Co-chairs, Thank you for the opportunity to say a few words.Â
My comments address issues related to technology transfer (TT), a topic we have been...
Commission report on competition enforcement in the pharmaceutical sector
Guest author Jacquelyn D. Veraldi is Assistant Professor of European Law at the University of Groningen. Guest author Tais A. Ruiz Palacios is a...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
The Expanding Reach of the European Patent Office. Good for Health?
The European Patent Office (EPO) is tasked with the examination of patent applications and the granting of patents when these applications meet the patentability...
Decision on intellectual property waiver over Covid technology on hold till 2021; what are...
Note: This article was edited on 19 December to include a statement from the EU supporting sharing of intellectual property, technology, and know-how transfer.
The...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...
2018 Round-up of Noteworthy Medicines Law and Policy Events
We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy.
January
The Chilean parliament started...